Lilly targets RNA medicines

Article Excerpt

ELI LILLY & CO., $276.44, is a buy. The company (New York symbol LLY; TSINetwork Rating: Above Average) (www.lilly.com; Shares o/s: 952.3 million; Market cap: $262.3 billion; Dividend yield: 1.4%) has announced that it’s building a new RNA medicine centre in Boston for $700 million. Eli Lilly’s investment in RNA follows an industry-wide embrace of the technology, fuelled in part by the success of mRNA vaccines for COVID-19. Meantime, the company’s prospects remain bright. The company has a strong drug portfolio and a full development pipeline. It spends a very high 25% of its sales on research and development. Eli Lilly is a buy. buy…